AI-069532/AI/NIAID NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2007	1
2008	3
2009	2
2011	2
2012	2
2013	3
2014	3
2015	2
2024	0

1

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE. Wanga V, et al. Pharmacogenet Genomics. 2015 Sep;25(9):450-61. doi: 10.1097/FPC.0000000000000156. Pharmacogenet Genomics. 2015. PMID: 26148204 Free PMC article. Clinical Trial.

2

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ. Lehmann DS, et al. Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106. Pharmacogenet Genomics. 2015. PMID: 25461247 Free PMC article.

3

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH. Haas DW, et al. J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11. J Antimicrob Chemother. 2014. PMID: 24729586 Free PMC article. Clinical Trial.

4

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.

Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW. Johnson DH, et al. Pharmacogenet Genomics. 2014 Apr;24(4):195-203. doi: 10.1097/FPC.0000000000000034. Pharmacogenet Genomics. 2014. PMID: 24557078 Free PMC article. Clinical Trial.

5

Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384.

Leger PD, Johnson DH, Robbins GK, Shafer RW, Clifford DB, Li J, McLaren PJ, Haas DW. Leger PD, et al. J Neurovirol. 2014 Jun;20(3):304-8. doi: 10.1007/s13365-014-0235-9. Epub 2014 Feb 20. J Neurovirol. 2014. PMID: 24554482 Free PMC article.

6

Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation.

Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube MP, Gerschenson M, Haas DW, Torriani FJ; Aids Clinical Trials Group A5152s And Dacs 252 Study Teams. Hulgan T, et al. AIDS Res Hum Retroviruses. 2013 Oct;29(10):1293-9. doi: 10.1089/aid.2013.0079. Epub 2013 Aug 14. AIDS Res Hum Retroviruses. 2013. PMID: 23944767 Free PMC article. Clinical Trial.

7

Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.

Gandhi RT, Bosch RJ, Aga E, Bedison MA, Bastow B, Schmitz JL, Siliciano JD, Siliciano RF, Eron JJ, Mellors JW; ACTG A5173 team. Gandhi RT, et al. Antivir Ther. 2013;18(4):607-13. doi: 10.3851/IMP2543. Epub 2013 Feb 15. Antivir Ther. 2013. PMID: 23411421 Free PMC article. Clinical Trial.

8

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW; DS Clinical Trials Group. Ribaudo HJ, et al. J Infect Dis. 2013 Feb 1;207(3):420-5. doi: 10.1093/infdis/jis690. Epub 2012 Nov 12. J Infect Dis. 2013. PMID: 23148286 Free PMC article. Clinical Trial.

9

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Holzinger ER, et al. Pharmacogenet Genomics. 2012 Dec;22(12):858-67. doi: 10.1097/FPC.0b013e32835a450b. Pharmacogenet Genomics. 2012. PMID: 23080225 Free PMC article.

10

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW; AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams. Haubrich RH, et al. AIDS. 2011 Nov 28;25(18):2269-78. doi: 10.1097/QAD.0b013e32834d0c20. AIDS. 2011. PMID: 21941167 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

17 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year